Please login to the form below

Not currently logged in
Email:
Password:

Eisai shares drop on failure of Aricept successor

Shares in Japan-based pharmaceutical company Eisai dropped 3.1 per cent to reach JPY 4,960 (USD 43.21) due to the failure of entacapone, the company's successor product to the Alzheimer's disease treatment, Aricept (donepezil).

Shares in Japan-based pharmaceutical company Eisai dropped 3.1 per cent to reach JPY 4,960 (USD 43.21) due to the failure of entacapone, the company's successor product to the Alzheimer's disease treatment, Aricept (donepezil).

One of three studies on entacapone, showed no advantage over a placebo, according to a company statement. As a result, the regulatory filing for the drug has been set back until 2009.

Eisai also revealed it would delay applying for FDA approval of its investigational breast cancer drug, E-7389. The company will now file in Q1 2008, instead of in the current quarter. If successful, E-7389 will be Eisai's first new product on the US market since 1998.

Sales of Aricept added to Eisai's recent posting of a 20 per cent profit rise in Q3 FY07. As a result, this is Eisai's biggest-selling product, the US patent of which will run out in  2010. Q3 FY07 sales for Aricept were JPY 73.5bn (USD 640.3m).

According to Daiwa Institute of Research analysts, the delay in developing entacapone would make it very difficult for Eisai to replace lost Aricept sales. They said they had been expecting the experimental drug to recover half of Aricept sales after its US patent expires in 2010.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...